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Impact of acute diabetes decompensation
on outcomes of diabetic patients admitted
with ST‑elevation myocardial infarction
Mayada Issa1†, Fahad Alqahtani2†, Chalak Berzingi2, Mohammad Al‑Hajji2, Tatiana Busu2
and Mohamad Alkhouli2,3*

Abstract
Background: Acute hyperglycemia is associated with worse outcomes in diabetic patients admitted with ST-eleva‑
tion myocardial infarction (STEMI). However, the impact of full-scale decompensated diabetes on STEMI outcomes has
not been investigated.
Methods: We utilized the national inpatient sample (2003–2014) to identify adult diabetic patients admitted with
STEMI. We defined decompensated diabetes as the presence of diabetic ketoacidosis (DKA) or hyperglycemic hyper‑
osmolar state (HHS). We compared in-hospital morbidity and mortality and cost between patients with and without
diabetes decompensation before and after propensity-score matching.
Results: A total of 73,722 diabetic patients admitted with STEMI were included in the study. Of those, 1131 (1.5%) suf‑
fered DKA or HSS during the hospitalization. After propensity-score matching, DKA/HHS remained associated with a
significant 32% increase in in-hospital mortality (25.6% vs. 19.4%, p = 0.001). The DKA/HHS group also had higher inci‑
dences of acute kidney injury (39.4% vs. 18.9%, p < 0.001), sepsis (7.3% vs. 4.9%, p = 0.022), blood transfusion (11.3%
vs. 8.2%) and a non-significant trend towards higher incidence of stroke (3.8% vs. 2.4%, p = 0.087). Also, DKA/HHS
diagnosis was associated with lower rates of referral to coronary angiography (51.5% vs. 55.5%, p = 0.023), coronary
stenting (26.1% vs. 34.8%, p < 0.001), or bypass grafting (6.2% vs. 8.7%, p = 0.033). Referral for invasive angiography was
associated with lower odds of death during the hospitalization (adjusted OR 0.66, 95%CI 0.44-0.98, p = 0.039).
Conclusions: Decompensated diabetes complicates ~ 1.5% of STEMI admissions in diabetic patients. It is associated
with lower rates of referral for angiography and revascularization, and a negative differential impact on in-hospital
morbidity and mortality and cost.
Keywords: Myocardial infarction, Diabetic ketoacidosis, Hyperosmolar hyperglycemic state, Coronary angiography,
Coronary stenting
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Background
The impact of acute hyperglycemia on clinical outcomes of diabetic and non-diabetic patients admitted
with ST-elevation myocardial infarction (STEMI) has
been extensively studied. High admission blood glucose
among STEMI patients is associated with higher shortterm incidences of failed reperfusion, acute kidney injury,
stent thrombosis, myocardial damage and death among
[1–12]. In addition, hyperglycemia during STEMI hospitalizations in diabetics predicted left ventricular remodeling and survival during long-term follow-up [13–18].
However, large-scale outcomes data of STEMI patients
with acutely decompensated diabetes manifesting as diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar state (HHS) are scarce [11]. We utilized a nationwide
representative sample to assess the contemporary trends
in the incidence and in-hospital morbidity and mortality
and cost of decompensated diabetes (defined as DKA or
HSS) among diabetic patients admitted with STEMI.
Methods
Study data

The National Inpatient Sample (NIS) was used to derive
patient relevant information between January, 1st 2003
and December, 31st 2014. The NIS is the largest publicly
available all-payer administrative claims-based database
and contains information about patient discharges from
approximately 1000 non-federal hospitals in 45 states. It
contains clinical and resource utilization information on
5–8 million discharges annually, with safeguards to protect the privacy of individual patients, physicians, and
hospitals. These data are stratified to represent approximately 20% of US inpatient hospitalizations across different hospital and geographic regions (random sample).
National estimates of the entire US hospitalized population were calculated using the Agency for Healthcare
Research and Quality sampling and weighting method.
Study population

Patients > 18-year-old with a principle discharge diagnosis of ST-elevation myocardial infarction (International Classification of Diseases-Ninth Revision-Clinical
Modification [ICD-9-CM] codes 410.×1 except 410.71)
between 2003 and 2014 were identified in the NIS. Nondiabetic patients were then excluded yielding a cohort of
diabetic patients admitted with STEMI. Those were then
stratified into patients with or without decompensated
diabetes. Similar to prior studies, we defined decompensated diabetes was defined as: diabetes with ketoacidosis (ICD-9-CM codes 250.10-250.13) or diabetes
with hyperosmolaity (ICD-9-CM codes 250.20-250.23)
[19, 20]. Myocardial infarction codes used in this study
have a negative predictive value of 96.1%, and a positive
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predictive value of 95.9% and are similar to what has been
reported in other studies [21, 22].
Outcomes analysis and study endpoints

A comparative analysis was performed between diabetic
patients admitted with STEMI with and without DKA/
HSS before and after propensity score matching for the
primary end point of in-hospital mortality, and for the
secondary end points of in-hospital complications, length
of stay, post-discharge intermediate care utilization and
cost.
To account for potential confounding factors and
reduce the effect of selection bias, a propensity scorematching model was developed using logistic regression
to derive two matched groups for the comparative outcomes analysis. Patients admitted with STEMI with or
without DKA/HHS were entered into a nearest neighbor
1:1 variable ratio, parallel, balanced propensity-matching model using a caliper of 0.01 without replacement
to ensure perfect matching. Variables included in the
propensity match model are listed in Additional file 1:
Table S1.
We anticipated that decompensated diabetes will have
a differential impact on referral patterns for invasive
angiography. We hence examined the impact of invasive angiography referral on in-hospital mortality among
patients with decompensated diabetes using a multivariable logistical regression analysis model.
Statistical analysis

Descriptive statistics presented as frequencies with percentages for categorical variables and as means with
standard deviations for continuous variables. Baseline characteristics were compared using a Pearson Chi
squared test and Fisher’s exact test for categorical variables and an independent-samples t test for continuous
variables. Matched categorical variables were presented
as frequencies with percentages and compared using
McNamar’s test. Matched continuous variables were presented as means with standard deviations and compared
using a paired-samples t-test. A type I error rate of < 0.05
was considered statistically significant. To assess monotonic trends of utilization and outcomes we employed the
non-parametric Mann-Kendal trend method. All statistical analyses were performed using SPSS version 24 (IBM
Corporation, Armonk, NY) and R, version 3.3.1.

Results
A total of 73,722 diabetic patients (weighted national
estimate = 362, 362) admitted with STEMI between January 1st, 2003 and December 31st, 2014 were included
in the study. Of those, 72,591 patients (98.5%) had compensated diabetes and 1131 (1.5%) suffered DKA or HSS
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during the hospitalization with modest temporal increase
in this incidence during the study period (Fig. 1). Patients
with DKA/HHS were younger (63 ± 15 vs. 67 ± 15 years,
p < 0.001) and a distinctive risk profile compared with
diabetic patients without DKA/HHS, characterized with
lower incidences of hypertension, hyperlipidemia, smoking, chronic obstructive lung disease, known coronary
artery disease, and prior atrial fibrillation (Table 1).
Patients with decompensated diabetes had higher incidences of cardiogenic shock (23.9% vs. 9.3%), and cardiac
arrest (11.8% vs. 5.6%), and were less likely to undergo
coronary angiography (51.4% vs. 61.1%), percutaneous
coronary intervention (PCI) (25.8% vs. 40%), or coronary
bypass grafting (6.2% vs. 9.2%) (P < 0.001 for all) (Tables 1,
2). However, referral to coronary angiography and PCI
increased overtime (Fig. 2).
Outcomes of the unmatched cohorts

Compared with patients with decompensated diabetes,
those with DKA/HHS had over twofold higher in-hospital mortality (26.4% vs. 11.9%, p < 0.001) and higher
incidences of acute kidney injury (40% vs. 13.3%), stroke
(3.7% vs. 1.6%), sepsis (7.5% vs. 1.9%), blood transfusion (11.3% vs. 8.2%) and mechanical ventilation (8.6%
vs. 2.9%), (p < 0.001 for all). They also had longer hospitalizations (7 ± 8 vs. 5 ± 6 days, p < 0.001), higher hospital charges (87,382 ± 132,119$ vs. 64,396 ± 81,185$,
p < 0.001), and were less likely to be discharged directly to
home (58.7% vs. 68.4%, p < 0.001) (Table 3).
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Outcomes of the matched cohorts

Following propensity-score matching, baseline characteristics between the two sets of STEMI patients with and
without DKA/HHS became well matched (Additional
file 1: Table 2 and Figure S1). The presence of DKA/
HHS remained associated with significantly lower rates
of referral to coronary angiography (52.2% vs. 57.1%,
p = 0.023), and PCI (29.5% vs. 38.4%, p < 0.001) (Additional file 1: Table S3). In these propensity-matched
cohorts, DKA/HHS remained associated with a significant 32% increase in in-hospital mortality (25.6% vs.
19.4%, p = 0.001). The DKA/HHS group also had significantly higher incidences of acute kidney injury (39.4% vs.
18.9%, p < 0.001), sepsis (7.3% vs. 4.9%, p = 0.022), and a
non-significant trend towards higher stroke (3.8% vs.
2.4%, p = 0.087). Similar to the unmatched cohorts, they
also had longer hospitalizations, higher hospital charges
and were less likely to be discharged directly to home
(Table 3).
Given that patients in the decompensated diabetes
group were less likely to be referred for invasive angiography and they also had higher in-hospital mortality, the
impact of invasive angiography referral on in-hospital
mortality among these patients was examined using a
multivariable logistical regression analysis model. This
model adjusted for demographics, baseline clinical risk
factors, insurance status and hospital characteristic, and
showed that referral for invasive angiography was associated with lower odds of death during the hospitalization

Fig. 1 Trends in the incidence of decompensated diabetes among diabetic patients admitted with STEMI
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Table 1 Baseline characteristics of the study’s population
Baseline characteristics

Compensated diabetes N = 72,591
NE = 356,810

Age-mean (SD), years

64 ± 14

Female

Decompensated diabetes N = 1113
NE = 5553
63 ± 15

P value
< 0.001

41.0%

47.3%

Caucasian

70.5%

70.1%

African American

10.5%

11.5%

Hispanic

11.1%

11.2%

Dyslipidemia

52.3%

32.4%

< 0.001

Hypertension

70.8%

51.7%

< 0.001

Prior sternotomy

7.3%

6.5%

Chronic lung disease

18.2%

13.7%

< 0.001

Atrial fibrillation/flutter

15.5%

12.0%

0.001

Anemia

16.1%

19.4%

Coagulopathy

4.0%

7.5%

Conduction abnormality

5.8%

7.2%

0.05

Congestive heart failure

0.7%

4.7%

< 0.001

Cardiogenic shock

9.3%

23.9%

< 0.001

Race

< 0.001
0.752

0.361

0.003
< 0.001

Drug abuse

1.4%

3.3%

< 0.001

Smoking

26.6%

20.6%

< 0.001

Vascular disease

10.4%

8.8%

Coronary artery disease

64.6%

48.4%

Prior stroke

3.3%

2.6%

0.182

Chronic renal failure

17.4%

21.2%

0.001

Liver disease

1.1%

2.0%

0.005

Teaching hospital

43.2%

44.8%

0.285

Rural hospital location

15.1%

12.5%

Primary payer-no (%)

0.077
< 0.001

0.016
< 0.001

Medicare/medicaid

65.1%

62.0%

Private insurance

25.3%

24.8%

Self-pay

6.0%

9.8%

No charge/other

3.7%

3.4%

SD standard deviation

Table 2 Management patterns in the unmatched cohorts
Management

Compensated
diabetes
N = 72,591
NE = 356,810
(%)

Decompensated
diabetes
N = 1113
NE = 5553 (%)

P value

Coronary angiography

62.9

52.3

< 0.001

Coronary intervention

43.2

29.6

< 0.001

IV thrombolysis

1.8

1.3

0.218

Underwent PTCA

3.2

3.7

0.308

Underwent PCI

40.0

25.8

< 0.001

  BMS

27.4

15.4

< 0.001

  DES

13.4

10.8

< 0.001

PTCApercutaneous transluminal coronary angiography, IV intravenous, PCI
percutaneous coronary intervention, BMS bare metal stent, DES drug eluting
stent

(adjusted OR 0.66, 95%CI 0.44–0.98, p = 0.039). Variables
included in this regression models are the same variables
used for propensity score matching outlined in Additional file 1: Table S1.

Discussion
The main findings of the present investigation are: (1)
acute diabetes decompensation occur in 1.5% of diabetics
admitted with STEMI, (2) those patients have less prevalence of previously diagnosed coronary artery disease,
but higher incidences of cardiogenic shock and cardiac
arrest, (3) patients with decompensated diabetes were
less likely to undergo coronary angiography and revascularization compared with patients with compensated
diabetes, (4) referral to angiography was independently
associated with lower risk-adjusted odds of in-hospital
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Fig. 2 Trends in percutaneous coronary revascularization among diabetic patients admitted with STEMI

Table 3 In-hospital outcomes of STEMI patients with and without DKA/HHS
Clinical outcome

Unmatched cohorts
Compensated
diabetes
N = 72,591
NE = 356,810
(%)

Decompensated diabetes
N = 1113 NE = 5553 (%)

Matched cohorts
P
value

Compensated diabetes
N = 1103 NE = 5410 (%)

Decompensated diabetes
N = 1103 NE = 5410 (%)

P value

Death

11.9

26.4

< 0.001 19.4

25.6

0.001

Blood transfusion

8.2

11.3

< 0.001 11.7

11.1

0.689
< 0.001

Acute kidney injury

13.3

40.0

< 0.001 18.9

39.4

New dialysis

0.4

0.5

0.521 0.5

0.5

0.99

Stroke

1.6

3.7

< 0.001 2.4

3.8

0.087

UTI

7.4

13.1

< 0.001 8.3

13.1

0.001

Sepsis

1.9

7.5

< 0.001 4.9

7.3

Acquired pneumonia

6.6

12.0

< 0.001 7.5

12.1

Mechanical ventilation 2.9

8.6

< 0.001 7.1

8.0

0.456

Tracheostomy

1.5

<0.001 2.6

1.0

0.006
0.01

0.6

Discharged home

60.3

43.3

< 0.001 51.0

44.1

Discharged to IC

26.9

29.1

28.3

29.2

5±6

7±8

LOS (mean ± SD)

Total charges ($)

64,396 ± 81,185 87,382 ± 132,119

< 0.001 6 ± 7

< 0.001 76,983 ± 109,872

UTI urinary tract infection, IC intermediate care facility, SD standard deviation, LOS length of stay

death in patients with decompensated diabetes, and (5)
acute diabetes decompensation was associated with 32%
higher in-hospital mortality, higher incidences of certain
key morbidities, more resource utilization, and higher
cost.
Prior studies have shown that the hyperglycemia during STEMI admissions is not uncommon in both diabetics and non-diabetics, and hyperglycemia in this setting
is associated with worse short and long-term outcomes
[1–18]. Nonetheless, to our knowledge, the incidence of
full-scale uncontrolled hyperglycemia (decompensated
diabetes) manifesting as DKA or HHS and its impact on

7±7

84,527 ± 125,828

0.022
< 0.001

0.02
0.133

clinical outcomes among STEMI patients have not been
previously investigated.
Our analysis reveals that the incidence of DKA or
HHS among diabetic patients admitted with STEMI is
low (1.5%) but is associated with lower odds of undergoing revascularization, and higher morbidity and
mortality and cost. Albeit intuitive, the findings of our
study deserve more scrutiny:
1. The lower prevalence of known coronary artery disease and the worse initial presentation (evident by
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the higher incidence of cardiogenic shock and cardiac arrest) in the DKA/HHS population are absorbing. Although speculative, these patients may have
constituted a different cohort of patients at baseline
that is characterized with worse chronic glycemic
control, attenuated symptoms due to diabetic neuropathy, delayed presentations, and possibly larger
infarcts [23, 24].
2. The interrelation between DKA/HHS and worse outcomes in STEMI patients is rather complex and may
be difficult to unravel from cohort analyses like the
present one. Several studies have shown than uncontrolled hyperglycemia is associated with high plasma
catecholamine levels, oxidative stress, and endothelial and microvascular dysfunction possibly leading
to higher incidence of no reflow, larger infarcts and
hence worse STEMI outcomes [1, 25, 26]. Vice versa,
the occurrence of DKA/HHS during a STEMI admission may be related to worse STEMI profile in these
patients (cardiogenic shock or cardiac arrest). These
patients may experience more intense hemodynamic and hormonal derangements and hence may
develop DKA or HHS as a result for their ‘higherrisk’ STEMI. Further studies are needed to delineate the impact of variable degrees of hyperglycemia
on STEMI outcomes and to identify the associated
underlying mechanisms.
3. Patients with DKA/HHS were less likely to be
referred to angiography, although this has improved
with time. Reasons for this ‘less invasive’ practice are
not known and can not be ascertained in our study.
Nonetheless, referral for angiography was independently associated with improved in hospital survival
suggesting a potential opportunity for improvement
in this cohort.
4. The excess associated mortality of DKA/HHS was
significantly attenuated after rigorous propensity
score matching: 26.4% vs. 11.9%, p < 0.001 before
matching, and 25.6% vs. 19.4%, p = 0.001 after matching. This suggests that baseline and hospital characteristics played a key role in the variance of outcomes
between the two groups.

Limitations
Our study has a number of limitations. (1) The NIS is an
administrative database that gathers data for billing purposes and can be limited by erroneous coding. Nevertheless, the Healthcare Cost and Utilization Project’s quality
control minimizes the discrepancies related to diagnosis
coding. Also, both the procedures and the hard clinical
endpoints reported in our study are hard to miscode. (2)
Angiographic data, and information on peri-procedural
hemodynamics, medications use, are not available in the
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NIS. (3) Similarly, granular data on blood glucose levels,
and insulin use as well as the timing of the DKA/HHS
diagnoses are not captured in NIS. (5) Pre-admission
diabetic control and anti-diabetic medications are not
included in this dataset. Several studies have suggested
a possible impact of Metformin and other anti-diabetics
on infarct size and outcomes in diabetic patients admitted with STEMI [27–29]. This potential effect can not be
assessed with the current study design. (4) Significant differences in baseline risk profiles were noted between the
two groups. The impact of unmeasured confounders on
the comparative analysis cannot be ruled out. Nonetheless, we believe that our rigorous propensity score matching should minimize that risk.

Conclusions
Decompensated diabetes complicates ~ 1.5% of STEMI
admissions in diabetic patients. It is associated with lower
rates of referral for angiography and revascularization,
and a negative differential impact on in-hospital morbidity and mortality and cost. Further studies are needed to
identify preventative and management strategies to mitigate the excess morbidity and mortality in these patients.
Additional file
Additional file 1: Table S1. Variables used for propensity score matching.
Table S2. Baseline characteristics of the propensity matched groups.
Table S3. Management patterns in the propensity matched cohorts.
Figure S1. Standardized mean differences before and after propensity
score matching.
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